Daratumumab in multiple myeloma.

ADP-ribosyl Cyclase 1 / immunology Amyloidosis / drug therapy Antibodies, Monoclonal / administration & dosage Antineoplastic Agents, Immunological / administration & dosage Antineoplastic Combined Chemotherapy Protocols / therapeutic use Drug Evaluation, Preclinical Drug Resistance, Neoplasm Humans Immunotherapy / methods Membrane Glycoproteins / immunology Multiple Myeloma / drug therapy Survival Rate Treatment Outcome
CD38 monoclonal antibody daratumumab infusion reactions myeloma myeloma management

Journal

Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236

Informations de publication

Date de publication:
15 07 2019
Historique:
received: 26 09 2018
revised: 11 12 2018
accepted: 03 01 2019
pubmed: 6 4 2019
medline: 9 4 2020
entrez: 6 4 2019
Statut: ppublish

Résumé

The development of effective monoclonal antibodies for the treatment of myeloma has been a long journey of clinical and drug development. Identification of the right target antigen was a critical part of the process. CD38 as a target has been considered for some time, but clinically, daratumumab, a CD38 monoclonal antibody, was the first to be tested, and it has delivered the best clinical responses as a single agent to date. Its proven safety and efficacy in combination with other antimyeloma agents have led to several US Food and Drug Administration approvals for treating myeloma. Furthermore, the results of early trials in the induction therapy setting have demonstrated a beneficial role when it is added to the existing induction regimens. This review summarizes the importance of CD38 as a target and examines the clinical development of the CD38 monoclonal antibody daratumumab and its clinical significance in combination regimens in both patients with relapsed/refractory myeloma and patients with newly diagnosed myeloma.

Identifiants

DOI: 10.1002/cncr.32065 PMID: 30951198
pubmed: 30951198
doi: 10.1002/cncr.32065
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antineoplastic Agents, Immunological 0
Membrane Glycoproteins 0
daratumumab 4Z63YK6E0E
CD38 protein, human EC 3.2.2.5
ADP-ribosyl Cyclase 1 EC 3.2.2.6

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2364-2382

Informations de copyright

© 2019 American Cancer Society.

Auteurs

Ajay K Nooka (AK)

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.
ORCID: 0000-0003-4165-6869

Jonathan L Kaufman (JL)

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.

Craig C Hofmeister (CC)

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.

Nisha S Joseph (NS)

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.
ORCID: 0000-0003-4001-9622

Thomas L Heffner (TL)

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.

Vikas A Gupta (VA)

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.

Harold C Sullivan (HC)

Department of Pathology, Emory University, Atlanta, Georgia.

Andrew S Neish (AS)

Department of Pathology, Emory University, Atlanta, Georgia.

Madhav V Dhodapkar (MV)

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.

Sagar Lonial (S)

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Glycoprotéines membranaires › Antigènes CD38 › Daratumumab in multiple myeloma.
questionsmedicales.fr › Maladies métaboliques et nutritionnelles › Maladies métaboliques › Troubles de l'homéostasie des protéines › Amyloïdose › Daratumumab in multiple myeloma.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Daratumumab in multiple myeloma.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Antinéoplasiques immunologiques › Daratumumab in multiple myeloma.
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › Daratumumab in multiple myeloma.
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Daratumumab in multiple myeloma.
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques › Daratumumab in multiple myeloma.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Daratumumab in multiple myeloma.
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › Daratumumab in multiple myeloma.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Glycoprotéines membranaires › Daratumumab in multiple myeloma.
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Paraprotéinémies › Myélome multiple › Daratumumab in multiple myeloma.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Mortalité › Taux de survie › Daratumumab in multiple myeloma.
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Daratumumab in multiple myeloma.